Target Price | CHF302.00 |
Price | CHF259.90 |
Potential | 16.20% |
Number of Estimates | 19 |
19 Analysts have issued a price target Roche 2026 . The average Roche target price is CHF302.00. This is 16.20% higher than the current stock price. The highest price target is CHF454.00 74.68% , the lowest is CHF220.00 15.35% . | |
A rating was issued by 24 analysts: 10 Analysts recommend Roche to buy, 10 to hold and 4 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Roche stock has an average upside potential 2026 of 16.20% . Most analysts recommend the Roche stock at Buy or hold. |
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion CHF | 60.50 | 63.51 |
3.03% | 4.99% | |
EBITDA Margin | 35.81% | 39.42% |
6.07% | 10.08% | |
Net Margin | 13.66% | 22.98% |
29.92% | 68.22% |
19 Analysts have issued a sales forecast Roche 2025 . The average Roche sales estimate is CHF63.5b . This is 4.99% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF67.0b 10.74% , the lowest is CHF60.7b 0.41% .
This results in the following potential growth metrics:
2024 | CHF60.5b | 3.03% |
---|---|---|
2025 | CHF63.5b | 4.99% |
2026 | CHF66.2b | 4.27% |
2027 | CHF68.9b | 4.00% |
2028 | CHF72.0b | 4.57% |
2029 | CHF75.1b | 4.29% |
16 Analysts have issued an Roche EBITDA forecast 2025. The average Roche EBITDA estimate is CHF25.0b . This is 19.01% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF26.2b 24.72% , the lowest is CHF21.9b 4.11% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | CHF21.7b | 9.28% |
---|---|---|
2025 | CHF25.0b | 15.57% |
2026 | CHF26.3b | 4.97% |
2027 | CHF27.2b | 3.55% |
2028 | CHF29.6b | 8.71% |
2029 | CHF29.4b | 0.47% |
2024 | 35.81% | 6.07% |
---|---|---|
2025 | 39.42% | 10.08% |
2026 | 39.68% | 0.66% |
2027 | 39.51% | 0.43% |
2028 | 41.07% | 3.95% |
2029 | 39.20% | 4.55% |
13 Roche Analysts have issued a net profit forecast 2025. The average Roche net profit estimate is CHF14.6b . This is 76.62% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF16.8b 103.04% , the lowest is CHF10.4b 25.99% .
This results in the following potential growth metrics and future Net Margins:
2024 | CHF8.3b | 27.80% |
---|---|---|
2025 | CHF14.6b | 76.62% |
2026 | CHF15.7b | 7.43% |
2027 | CHF16.7b | 6.22% |
2028 | CHF17.1b | 2.44% |
2029 | CHF19.0b | 11.11% |
2024 | 13.66% | 29.92% |
---|---|---|
2025 | 22.98% | 68.22% |
2026 | 23.68% | 3.05% |
2027 | 24.18% | 2.11% |
2028 | 23.69% | 2.03% |
2029 | 25.24% | 6.54% |
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share CHF | 10.39 | 18.35 |
27.80% | 76.61% | |
P/E | 14.16 | |
EV/Sales | 3.62 |
13 Analysts have issued a Roche forecast for earnings per share. The average Roche EPS is CHF18.35 . This is 76.61% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF21.10 103.08% , the lowest is CHF13.09 25.99% .
This results in the following potential growth metrics and future valuations:
2024 | CHF10.39 | 27.80% |
---|---|---|
2025 | CHF18.35 | 76.61% |
2026 | CHF19.71 | 7.41% |
2027 | CHF20.94 | 6.24% |
2028 | CHF21.45 | 2.44% |
2029 | CHF23.84 | 11.14% |
Current | 25.01 | 65.74% |
---|---|---|
2025 | 14.16 | 43.38% |
2026 | 13.18 | 6.92% |
2027 | 12.41 | 5.84% |
2028 | 12.12 | 2.34% |
2029 | 10.90 | 10.07% |
Based on analysts' sales estimates for 2025, the Roche stock is valued at an EV/Sales of 3.62 and an P/S ratio of 3.25 .
This results in the following potential growth metrics and future valuations:
Current | 3.80 | 13.10% |
---|---|---|
2025 | 3.62 | 4.64% |
2026 | 3.48 | 4.10% |
2027 | 3.34 | 3.84% |
2028 | 3.20 | 4.37% |
2029 | 3.06 | 4.11% |
Current | 3.42 | 15.82% |
---|---|---|
2025 | 3.25 | 4.75% |
2026 | 3.12 | 4.10% |
2027 | 3.00 | 3.84% |
2028 | 2.87 | 4.37% |
2029 | 2.75 | 4.11% |
Analyst | Rating | Action | Date |
---|---|---|---|
BERENBERG |
Hold
➜
Hold
|
Unchanged | Apr 07 2025 |
TD COWEN |
Hold
➜
Hold
|
Unchanged | Apr 06 2025 |
HSBC |
Buy
➜
Buy
|
Unchanged | Mar 23 2025 |
REDBURN ATLANTIC |
Buy
➜
Buy
|
Unchanged | Mar 21 2025 |
JEFFERIES |
Hold
➜
Hold
|
Unchanged | Mar 11 2025 |
STIFEL EUROPE |
Hold
➜
Hold
|
Unchanged | Mar 02 2025 |
DZ BANK |
Buy
➜
Buy
|
Unchanged | Feb 02 2025 |
Analyst Rating | Date |
---|---|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Apr 07 2025 |
Unchanged
TD COWEN:
Hold
➜
Hold
|
Apr 06 2025 |
Unchanged
HSBC:
Buy
➜
Buy
|
Mar 23 2025 |
Unchanged
REDBURN ATLANTIC:
Buy
➜
Buy
|
Mar 21 2025 |
Unchanged
JEFFERIES:
Hold
➜
Hold
|
Mar 11 2025 |
Unchanged
STIFEL EUROPE:
Hold
➜
Hold
|
Mar 02 2025 |
Unchanged
DZ BANK:
Buy
➜
Buy
|
Feb 02 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.